Anil Ekkati

Anil Ekkati has extensive work experience in the field of pharmaceutical research and development. Anil started their career at Wayne State University as a Postdoctoral Researcher, where they focused on developing catalytic inhibitors to lower dosage, treatment costs, and side effects. Anil then moved on to Yale University as a Postdoctoral Research Scientist, where they conducted research on the design and synthesis of novel scaffolds for anti-cancer and anti-infectious agents.

After their time at Yale, Anil joined Weill Cornell Medicine, The Milstein Synthetic Chemistry Core Facility as a Research Scientist. Here, they collaborated with scientists and clinicians to develop small molecule-based therapeutic agents and conducted scale-up synthesis of inhibitors for clinical testing.

Anil then transitioned to ChemGenes as a Senior Scientist, before joining Beth Israel Deaconess Medical Center, Harvard Medical School as a Research Scientist. At Beth Israel, they conducted a patent review of IDO1 inhibitors for cancer.

Their next role was at Merck, where they worked as a Research Scientist and later as a Principal Scientist-I. Anil played a key role in the process development of various API's and also contributed to several publications in the field.

Anil then joined Vertex Pharmaceuticals as a Senior Scientist, where they continued their research in drug development. Anil later moved on to Organix, Inc. and Veranova, both as a Senior Scientist-II.

Throughout their career, Anil has demonstrated expertise in process development, hit-to-lead optimization, target identification, and therapeutic agent synthesis.

Anil Ekkati obtained a Doctor of Philosophy (Ph.D.) degree in Organic Chemistry from Michigan Technological University. Their education at the university spanned from 2001 to 2006.